Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.

Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.

Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.

Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.

Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.

Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.

Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.

Abstract: The present invention discloses specific miRNAs as novel biomarkers and therapeutic targets in the treatment of heart failure. Methods of treating or preventing heart failure in a subject by administering mimics or inhibitors of these particular miRNAs are disclosed. A method of diagnosing or prognosing heart failure in a subject by determining the level of expression of one or more miRNAs is also described.

Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention. Formula (I).

Abstract: The present invention provides methods and apparatuses for predicting mortality and determining the likelihood of success of ?-blocker therapy in a patient who has suffered non-ischemic heart failure as well as providing probability of short-term and/or long term survival rate of a non-ischemic heart failure patient. In addition, the present invention provides a method for determining a treatment procedure for a non-ischemic heart failure patient.

Abstract: Embodiments of the invention are directed to identifying or treating a patient that would benefit from phosphodiesterase inhibitor therapy.

Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention. Formula (I).

Abstract: The present invention discloses specific miRNAs as novel biomarkers and therapeutic targets in the treatment of heart failure. Methods of treating or preventing heart failure in a subject by administering mimics or inhibitors of these particular miRNAs are disclosed. A method of diagnosing or prognosing heart failure in a subject by determining the level of expression of one or more miRNAs is also described.

Abstract: The present invention provides for methods of treating and preventing cardiac hypertrophy and heart failure. The present invention provides the link between ERK1/2 and calcineurin and CamKII. The present invention further demonstrates that inhibitors of ERK1/2 inhibit cardiac hypertrophy and heart disease by inhibiting, in part, the fetal cardiac gene expression that occurs when Ca2+-dependent signalling occurs in the heart.

Abstract: The invention provides a method of treating myocardial failure in a human. The method comprises administering an effective amount of transgene encoding ?-MHC that directly causes an increase in the quantity of ?-MHC in the myocardial tissue of the heart.

Abstract: The present invention provides methods of diagnosing myocardial failure in a human. The methods comprise obtaining a sample of myocardial tissue from a ventricle of the heart. In one embodiment, the expression of ?-myosin heavy chain, ?-myosin heavy chain, or both, are quantitated and their expression levels compared to that seen normal human ventricular myocardial tissues. In another embodiment, the expression of ?1-thyroid hormone receptor, ?2-thyroid hormone receptor, a ?1-thyroid hormone receptor+?1-thyroid hormone receptor, or combinations thereof, are quantitated, and their expression levels compared to that seen normal human ventricular myocardial tissues. Therapeutic interventions based on altering the expression of the aforementioned genes also are provide.

Abstract: The invention provides methods of diagnosing myocardial failure in a human. The methods comprise obtaining a sample of myocardial tissue from a ventricle of the heart of the human. In one method, the expression of &agr;-myosin heavy chain ((&agr;-MHC), &bgr;-myosin heavy chain (&bgr;-MHC), or both in the sample is quantitated, and it is determined by statistical analysis if the expression of &agr;-MHC, &bgr;-MHC, or both in the sample is significantly different than their expression in normal human ventricular myocardial tissue. A second method comprises quantitating the expression of &agr;1-thyroid hormone receptor (&agr;1-THR), &agr;2-THR, &agr;1-THR+&bgr;1-THR, or combinations thereof in the sample, and determining by statistical analysis if the expression of &agr;1-THR, &agr;2-THR, or &agr;1-THR+&bgr;1-THR in the sample is significantly different than their expression in normal human ventricular myocardial tissue.

Abstract: Methods for the identification of genes involved in cardiac disease states are provided. The methods compare gene expression between diseased and therapeutically treated patients. Through the identification of new targets, additional methods for drug screening and therapy also are provided.

Abstract: The invention provides a transgenic mouse that is a model for heart muscle disease and heart failure. Also provided are methods of using the transgenic mouse model to study heart muscle disease and heart failure and conditions and treatments related thereto.

Abstract: Disclosed are methods to identify adrenergic receptor antagonists having good tolerability. These methods include measuring the inverse agonist activity and/or the intrinsic sympathomimetic activity of an adrenergic receptor antagonist. Also disclosed are a method to treat heart failure and compounds useful therefor.